Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development

Area of Science:

• Hepatology
• Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent cancer with increasing incidence worldwide.
• Key risk factors include viral hepatitis, aflatoxin B1, alcoholism, and obesity.
• Obesity-associated non-alcoholic fatty liver disease (NAFLD) can progress to non-alcoholic steatohepatitis (NASH), impacting liver function.

Purpose of the Study:

• To review recent novel mechanisms linking non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC) progression.
• To highlight the role of inflammation, particularly gut-derived inflammation, in NASH-driven HCC.
• To provide an overview of emerging pathways in liver cancer development associated with metabolic dysfunction.

Main Methods:

• Literature review of recent scientific publications.
• Focus on studies investigating mechanisms of NASH-induced liver injury and HCC.
• Analysis of research on inflammatory pathways and gut microbiota contributions.

Main Results:

• NASH is increasingly recognized as a significant driver of HCC, independent of traditional risk factors.
• Inflammatory processes, including those originating from the gut microbiome, play a critical role in NASH pathogenesis and HCC development.
• Novel molecular and cellular mechanisms are being elucidated that connect metabolic dysregulation in NASH to hepatocarcinogenesis.

Conclusions:

• Understanding the intricate mechanisms of NASH-driven HCC is crucial for developing targeted therapies.
• Inflammation and gut dysbiosis are key therapeutic targets for preventing and treating liver cancer in NASH patients.
• Further research is needed to fully characterize these pathways and translate findings into clinical practice.